Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report

Abstract Background Pembrolizumab is an immune-checkpoints inhibitor that enhances the immune response against cancer cells and therefore is useful for the treatment of several carcinomas. However, pembrolizumab sometimes perturbs the immune system resulting in various autoimmune neurological compli...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hikaru Kamo, Taku Hatano, Kazuaki Kanai, Nozomi Aoki, Daiki Kamiyama, Kazumasa Yokoyama, Masashi Takanashi, Yuri Yamashita, Yasushi Shimo, Nobutaka Hattori
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2019-08-01
Edice:	BMC Neurology
Témata:	Pembrolizumab Necrotizing myositis ICPIs-related systemic myositis Ocular myositis Immune-related adverse events Myasthenia gravis
On-line přístup:	http://link.springer.com/article/10.1186/s12883-019-1416-1
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!